ERG rearrangement in local recurrences compared to distant metastases of castration-resistant prostate cancer.

Castration-resistant prostate cancer is the second most common cause of cancer death and results in a median survival of less than 2 years. In prostate cancer, fusions between TMPRSS2 and ERG are common. The ERG rearrangement prevalence in local recurrent castration-resistant prostate cancer compare...

Descripción completa

Detalles Bibliográficos
Publicado en:Virchows Archiv: European Journal of Pathology Vol. 461; no. 2; pp. 157 - 163
Autores principales: Scheble VJ, Scharf G, Braun M, Ruiz C, Stürm S, Petersen K, Beschorner R, Bachmann A, Zellweger T, Fend F, Kristiansen G, Bubendorf L, Wernert N, Shaikhibrahim Z, Perner S, Scheble, Veit J, Scharf, Gregor, Braun, Martin, Ruiz, Christian, Stürm, Susanna
Formato: research Journal Article
Publicado: Springer Nature Aug2012
Acceso en línea:Ver este registro en EBSCOhost
fields @attributes:
  recordID: 1
pdfLink:
plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=104444643&site=ehost-live
header:
  @attributes:
    shortDbName: ccm
    uiTerm: 104444643
    longDbName: CINAHL Complete
    uiTag: AN
  controlInfo:
    bkinfo:
    dissinfo:
    jinfo:
      jid:
        09456317
        O1Z
      jtl: Virchows Archiv: European Journal of Pathology
      issn: 09456317
      maglogo: N
    pubinfo:
      dt: Aug2012
      vid: 461
      iid: 2
      pid: 237
      pub: Springer Nature
      place: New York, New York
    artinfo:
      ui:
        104444643
        NLM22767266
        2011753822
        10.1007/s00428-012-1270-7
        NLM22767266
        104444643
      ppf: 157
      ppct: 6
      formats:
        fmt:
          @attributes:
            type: P
      tig:
        atl: ERG rearrangement in local recurrences compared to distant metastases of castration-resistant prostate cancer.
      aug:
        au:
          Scheble VJ
          Scharf G
          Braun M
          Ruiz C
          Stürm S
          Petersen K
          Beschorner R
          Bachmann A
          Zellweger T
          Fend F
          Kristiansen G
          Bubendorf L
          Wernert N
          Shaikhibrahim Z
          Perner S
          Scheble, Veit J
          Scharf, Gregor
          Braun, Martin
          Ruiz, Christian
          Stürm, Susanna
        affil: Institute of Pathology, University Hospital Tuebingen, Tuebingen, Germany
      sug:
        subj:
          Drug Resistance, Neoplasm
          Genes
          Prostatic Neoplasms
          Prostatic Neoplasms Pathology
          Proteins
          Antineoplastic Agents, Hormonal Therapeutic Use
          Surgery, Urogenital Methods
          Gene Amplification
          In Situ Hybridization, Fluorescence
          Male
          Neoplasm Metastasis
          Neoplasm Recurrence, Local
          Neoplasm Recurrence, Local Pathology
          Prostatic Neoplasms Drug Therapy
          Receptors, Cell Surface
          Tissue Array Analysis
          Male
      ab: Castration-resistant prostate cancer is the second most common cause of cancer death and results in a median survival of less than 2 years. In prostate cancer, fusions between TMPRSS2 and ERG are common. The ERG rearrangement prevalence in local recurrent castration-resistant prostate cancer compared to distant metastatic prostate cancer is unknown. We investigated the frequency of ERG rearrangement in local recurrent castration-resistant prostate cancer compared to distant metastatic prostate cancer, and assessed for associations between androgen receptor (AR) amplification and ERG rearrangement status. Samples from 134 patients diagnosed with prostate cancer (84 local recurrent castration resistant prostate cancer, 55 distant metastatic prostate cancer) were assessed for their ERG rearrangement and AR amplification status by fluorescence in situ hybridization. Statistical analysis was performed using the χ (2) test. We found that the ERG rearrangement occurs at a significantly lower frequency in distant metastatic prostate cancer (25 %) than in local recurrent castration-resistant prostate cancer (45 %). The AR amplification frequencies were 45 and 35 % in local recurrent castration-resistant prostate cancer and distant metastatic prostate cancer, respectively. The ERG rearrangement occurred at a lower frequency in distant metastatic prostate cancer compared to local recurrent castration-resistant prostate cancer.
      pubtype: Academic Journal
      doctype:
        research
        Journal Article
      ougenre: Article
    language: English
    refInfo:
    holdings:
      @attributes:
        islocal: N